We are thrilled to announce the launch of #LeishGenR - Precision Drug Resistance Diagnostics for #Leishmania directly from clinical samples 🚀 ⭐ 🧬 Join the Future of #Leishmaniosis Management! 🧬 ⭐ #LeishGenR is more than a tool – it is your partner in informed therapeutic decision-making, providing drug-resistance biomarkers for allopurinol, pentavalent antimonials, and miltefosine Contact #Nano1Health at info@nano1health.com to learn how #LeishGenR can transform your clinical practice and improve patient outcomes
Nano1Health - n1h
Investigación biotecnológica
Bellaterra, Barcelona 245 seguidores
Real-time metagenomics for infection surveillance and genomic epidemiology from a One-Health approach
Sobre nosotros
Nano1Health is a knowledge-based company. We are scientists with cross-cutting expertise in genetics, epidemiology, infectious diseases, clinical diagnosis, and bioinformatics. We apply our knowledge to genome sequencing in the context of infectious diseases, now implementing nanopore sequencing from a One Health approach. We also work in metagenomics approaches to discover and characterize the vast variability of new microorganisms in animal health and disease and the environment.
- Sector
- Investigación biotecnológica
- Tamaño de la empresa
- De 2 a 10 empleados
- Sede
- Bellaterra, Barcelona
- Tipo
- De financiación privada
- Fundación
- 2020
- Especialidades
- infectious disease, genomics, metagenomics, nanopore, clinical diagnose, One Health, animal health y environment
Ubicaciones
-
Principal
Cómo llegar
Ed Eureka. Parc de Recerca UAB. Campus UAB
Bellaterra, Barcelona 08195, ES
Empleados en Nano1Health - n1h
-
Olga Francino
Researcher @UAB. Founding Partner @Nano1Health and @Vetgenomics (CEO).
-
Joan Martí Carreras
R&D Project Manager and Consultant - #Diagnostics #Product development #Infectious diseases #Microbiome #Sequencing #Bioinformatics
-
Marina Carrasco Martin
Product development | Genomics | Project management | Industrial PhD
Actualizaciones
-
Nano1Health - n1h ha compartido esto
Welcome to Nano1Health - n1h feed. It's our pleasure to begin posting about us with some of our latest awards Well deserved Marina Carrasco Martin and team Joan Martí Carreras Xavier Roura Lluís Ferrer Caubet Marc Noguera Julian Daniel Perez Rodriguez In the next weeks, we'll be posting info about our company, and new results from our research and projects to keep you updated. You can also access them at www.nano1health.com Nanonews
I don't know when the "Highly commended" badge appears on our poster. However, on Thursday 23rd May, at the closing ceremony of the #LC2024 #LondonCalling2024 conference, we were honored to receive this award🫱🏻🫲🏼. "CNVs and drug-resistance in Leishmania infantum infecting dogs and humans" recipe Ingredients: • International network of collaborators • A chort of 46 L. infantum cultures • Whole Genome Sequencing using ONT Preparation: • LeishGenApp* * LeishGenApp is a diagnostic platform that facilitates treatment selection for each case of canine🐶 or human🧍♂️ leishmaniasis. Aids veterinarians👩🏼⚕️ and doctors🧑🏾⚕️in selecting the best drug among the 5 first-line treatments😊. The core of this platform is a panel of resistance biomarkers targeting the 5 first-line drugs used in L.infantum treatment🧬. Many thanks to the organization for this unmissable event, to the researchers and industry leaders we talked with, and deep deep thanks to our Nano1Health - n1h and VETGENOMICS SL team, especially to Olga Francino🫂
-
-
Nano1Health - n1h ha compartido esto
New paper looking at numbers of Leishmania positive dogs being diagnosed in the UK. Vital data in helping to assess the situation in the UK and showing how vigilant vets should be in screening imported dogs for Leishmania, as well as including leishmaniosis as a differential in dogs with relevant clinical signs. Thank you to ESCCAP colleague Guadalupe Miró Corrales and her co authors for a fascinating paper! https://lnkd.in/eexBMsfC.
-
🌍 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻 supports the global 𝗢𝗻𝗲 𝗛𝗲𝗮𝗹𝘁𝗵 initiative by addressing drug resistance in 𝘓𝘦𝘪𝘴𝘩𝘮𝘢𝘯𝘪𝘢 𝘪𝘯𝘧𝘢𝘯𝘵𝘶𝘮. 🔬 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻𝗔𝗽𝗽 and 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻𝗥 empower researchers, veterinarians, and clinicians with tools to manage zoonotic diseases through advanced genomics. 💡 By bridging the gap between human and animal health, 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻 contributes to sustainable healthcare strategies worldwide. #OneHealth #Leishmania #ZoonoticDiseases #DrugResistance https://lnkd.in/dc4wGzuP
LeishGen: Advanced Genomic Platforms for Drug Resistance Biomarkers in Leishmania infantum
nano1health.com
-
⚡ 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻𝗥 revolutionizes diagnostics for drug resistance in 𝘓𝘦𝘪𝘴𝘩𝘮𝘢𝘯𝘪𝘢 𝘪𝘯𝘧𝘢𝘯𝘵𝘶𝘮. ✔️ Detects resistance markers for allopurinol, antimonials & miltefosine from clinical samples (>5000 parasites/mL). ✔️ Results in less than 24 hours, enabling timely therapeutic decisions in high-demand clinical settings. ✔️ Designed with clinicians in mind, validated for accuracy even with low parasite loads. Advance your practice with this cutting-edge solution to combat drug resistance. https://lnkd.in/dc4wGzuP #LeishGenR #Leishmania #RapidDiagnostics #DrugResistance
LeishGen: Advanced Genomic Platforms for Drug Resistance Biomarkers in Leishmania infantum
nano1health.com
-
🧬 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻𝗔𝗽𝗽 offers unparalleled insights into the genome of 𝘓𝘦𝘪𝘴𝘩𝘮𝘢𝘯𝘪𝘢 𝘪𝘯𝘧𝘢𝘯𝘵𝘶𝘮. ✔️ Whole-genome sequencing with a 15-biomarker panel targeting drug resistance. ✔️ Comprehensive analysis delivered in 2 weeks, supporting precision medicine and tailored treatment decisions. ✔️ Applications in research and clinical settings for both human and animal health. Explore how 𝗟𝗲𝗶𝘴𝗵𝗚𝗲𝗻𝗔𝗽𝗽 can transform the future of genomic-driven healthcare. https://lnkd.in/dc4wGzuP #LeishGenApp #Leishmania #OneHealth #Genomics #PrecisionMedicine
LeishGen: Advanced Genomic Platforms for Drug Resistance Biomarkers in Leishmania infantum
nano1health.com
-
📢 𝗡𝗮𝗻𝗼𝟭𝗛𝗲𝗮𝗹𝘁𝗵 proudly introduces 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻, an innovative solution to tackle drug resistance in 𝘓𝘦𝘪𝘴𝘩𝘮𝘢𝘯𝘪𝘢 𝘪𝘯𝘧𝘢𝘯𝘵𝘶𝘮. 🧬 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻𝗔𝗽𝗽: Whole-genome sequencing and a 15-biomarker panel, delivering comprehensive resistance reports in just 2 weeks. ⚡ 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻𝗥: Rapid detection of resistance markers directly from clinical samples, providing results in under 24 hours. 🔬 Together, these platforms empower precision medicine while advancing the One Health approach by addressing resistance at the human-animal-environment interface. #LeishGen #Leishmania #OneHealth #DrugResistance https://lnkd.in/dc4wGzuP
-
-
Parte 3/3: LeishGenR: diagnósticos rápidos y precisos directamente desde muestras clínicas. ⚡ 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻𝗥 proporciona un enfoque rápido y directo para detectar biomarcadores de resistencia en 𝘓𝘦𝘪𝘴𝘩𝘮𝘢𝘯𝘪𝘢 𝘪𝘯𝘧𝘢𝘯𝘵𝘶𝘮. ✔️ Detecta biomarcadores de alopurinol, miltefosina y antimoniales desde muestras clínicas (>5000 parásitos/mL). ✔️ Resultados en menos de 24 horas, ideal para regiones endémicas donde las decisiones rápidas son cruciales. ✔️ Validado frente a secuenciación genómica para garantizar alta precisión. Diseñado para clínicos que buscan simplificar el diagnóstico y mejorar los resultados terapéuticos en pacientes. #Leishmania #resistencia #LeishGen https://lnkd.in/dGY2GpQ9
LeishGen: Plataformas genómicas avanzadas para biomarcadores de resistencia a fármacos en Leishmania infantum
nano1health.com
-
Parte 2/3: Profundizamos en LeishGenApp: análisis genómico avanzado para biomarcadores de resistencia. 🔬 𝗟𝗲𝗶𝘀𝗵𝗚𝗲𝗻𝗔𝗽𝗽 redefine el análisis genómico en 𝘓𝘦𝘪𝘴𝘩𝘮𝘢𝘯𝘪𝘢 𝘪𝘯𝘧𝘢𝘯𝘵𝘶𝘮. ✔️ Panel de 15 biomarcadores de resistencia basado en CNVs y variantes estructurales. ✔️ Secuenciación completa del genoma con datos detallados en solo 2 semanas. ✔️ Aplicaciones en estudios epidemiológicos y clínicos en humanos y animales. Diseñado para investigadores y clínicos, 𝗟𝗲𝗶𝘴𝗵𝗚𝗲𝗻𝗔𝗽𝗽 ofrece un enfoque integral que facilita decisiones terapéuticas basadas en genómica. #Leishmania #resistencia #LeishGen https://lnkd.in/dGY2GpQ9
LeishGen: Plataformas genómicas avanzadas para biomarcadores de resistencia a fármacos en Leishmania infantum
nano1health.com